news

Vaccines “essential” for addressing AMR, says WHO

2
SHARES

The World Health Organization (WHO) asserts that vaccines could reduce antibiotic use as well as economic costs of antimicrobial resistance (AMR) worldwide.

antimicrobial resistance (AMR) vaccine

A new report by the World Health Organization (WHO) has emphasised the importance of vaccines in addressing antimicrobial resistance (AMR) globally.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

For example, the report explained that “vaccines against 24 pathogens could reduce the number of antibiotics needed by 22 percent or 2.5 billion defined daily doses globally every year”.

Vaccines are a key part of helping to reducing AMR because they “prevent infections… and slow the emergence and spread of drug-resistant pathogens”, WHO explained.

The organisation’s report offers recommendations aimed at stakeholders, to improve the impact that vaccines have on AMR.

Turning the tide on AMR

WHO shared that a political declaration approved on 26 September at the 79th United Nations General Assembly High-Level Meeting on AMR, committed to clear goals and actions. These included the importance of patient access to medicines and treatments, in addition to initiatives to accelerate innovation and development in overcoming AMR.

The new report elaborates on an earlier WHO study. The research highlighted that current vaccines for pneumococcus pneumonia, Haemophilus influenzae type B and typhoid could prevent up to 106,000 of AMR-associated fatalities annually.

vaccines against 24 pathogens could reduce the number of antibiotics needed by 22 percent or 2.5 billion defined daily doses globally every year”

A further 543,000 of these deaths could be avoided worldwide with new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, according to the study.

WHO explained that new vaccines for tuberculosis are in clinical development and one for Klebsiella pneumoniae is in early development.

“Addressing antimicrobial resistance starts with preventing infections, and vaccines are among the most powerful tools for doing that,” commented Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Prevention is better than cure, and increasing access to existing vaccines and developing new ones for critical diseases, like tuberculosis, is critical to saving lives and turning the tide on AMR.” 

Share via
Share via